Drug Trial Radar · NCT03363321
PF-06741086 Long-term Treatment in Severe Hemophilia
Last checked: Nov 20, 2026Latest source record: Jul 27, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
20
Actual
Start
May 30, 2018
Primary completion
Aug 5, 2020
Study completion Aug 5, 2020
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Dec 6, 2017
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 12 years, up to 74 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is designed to evaluate the safety, tolerability and efficacy of long-term treatment with PF-06741086 in subjects with severe hemophilia who participated in the 3-month Phase 1b/2 B7841002 study. Additionally, de novo subjects will be recruited into this study.
Conditions
- Hemophilia A or B
Interventions
PF-06741086Biological
PF-06741086 subcutaneous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment-Emergent Adverse Events (TEAEs), TEAEs by Severity, and Serious Adverse Events (SAEs) (All Causality and Treatment-Related)Time frame: Day 1 up to Day 393
- Number of Participants With Abnormal Laboratory Findings Without Regard to Baseline Abnormality (Including Hematology, Serum Chemistry, and Urinalysis)Time frame: Hematology and serum chemistry: Baseline, Days 1, 29, 57, 85, 169, 253, and 365 visits. Urinalysis: Baseline, Days 1, 85, 169, 253, and 365 visits.
- Number of Participants With Changes From Baseline in Vital Signs Measurements Meeting the Pre-Defined Categorical Summarization CriteriaTime frame: Baseline, Days 1, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, 337, 365 and 393 visits.
- Number of Participants With Change From Baseline in Electrocardiogram (ECG) Parameters Meeting the Pre-defined Categorical Summarization CriteriaTime frame: Baseline, Days 1 and 29 visits
- Number of Participants With Abnormalities in Physical Examination FindingsTime frame: Day 1 to Day 393
- Number of Participants With Injection Site ReactionsTime frame: Day 1 to Day 365, and Day 393 visit.
Locations
8 sites in 7 countries. Site status is shown where the registry gives one.
UC Denver Hemophilia and Thrombosis Center
Aurora, Colorado
Centro de Hematologia e Hemoterapia de Campinas- Hemocentro de Campinas
Campinas, São Paulo, Brazil
Hospital Dr. Sotero del Rio
Santiago, Puente ALTO, Chile
Klinicki bolnicki centar Zagreb
Zagreb, Croatia
Klinika Hematologii i Transplantologii Uniwersyteckie Centrum Kliniczne
Gdansk, Poland
Phoenix Pharma (Pty) Ltd
Port Elizabeth, Eastern Cape, South Africa
Charlotte Maxeke Johannesburg Academic Hospital
Johannesburg, Gauteng, South Africa
UniversitatsSpital Zurich
Zurich, Switzerland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.